<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428842</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2013-02 BIO-RAIDs</org_study_id>
    <nct_id>NCT02428842</nct_id>
  </id_info>
  <brief_title>Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)</brief_title>
  <acronym>BIO-RAIDs</acronym>
  <official_title>Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Multicentric European trial for Cervical cancer, not previously treated, with&#xD;
      tumour biopsies, and blood collection for molecular analysis at predetermined time points.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between tumor biological profile and treatment response.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Dominant mutations and activation pathways in cervical cancers is assessed from tumor biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival evaluation</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Number of patient with no local/metastasis relapse 18 months after end of primary treatment course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard treatment description (Description of primary treatment course regarding : - Initial FIGO ( International Federation of Gynecology and Obstetrics ) staging at baseline - Geographic location(country)</measure>
    <time_frame>up to six months</time_frame>
    <description>Description of primary treatment course regarding :&#xD;
Initial FIGO ( International Federation of Gynecology and Obstetrics&#xD;
) staging at baseline&#xD;
Geographic location(country)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard treatment's side effects description (assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale - National Cancer Institute Common Toxicity Criteria for Adverse Effects)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Description of standard treatment's side effects will be assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular tumor alterations description (Description of molecular tumor alterations regarding geographic location (country)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Description of molecular tumor alterations regarding geographic location (country)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">419</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient will undergo standard care with tumor and blood sampling before and after treatment.&#xD;
Blood and tumor sampling will also be performed at disease progression/relapse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsies</intervention_name>
    <description>Tumor biopsies will be performed before and after treatment.</description>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling will be performed before and after treatment.</description>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. No prior treatment for cervical cancer.&#xD;
&#xD;
          2. FIGO Stage IB1 to IVB; all histological subtypes (excluding neuro-endocrine type).&#xD;
&#xD;
          3. Pelvic MRI available or planned before the start of treatment, , if FIGO ≥ IB2. and&#xD;
             optional for IB1 stage&#xD;
&#xD;
          4. Possibility to communicate imaging data by CD-ROM (format DICOM 3.0 or more).&#xD;
&#xD;
          5. Disease amenable to biopsy (3 tumour samples are mandatory prior to treatment).&#xD;
&#xD;
          6. Age ≥ 18 years.&#xD;
&#xD;
          7. ECOG (Eastern Cooperative Oncology Group) 0-2.&#xD;
&#xD;
          8. Life expectancy &gt; 6 months.&#xD;
&#xD;
          9. Patient eligible for standard treatment (according to standards of each center).&#xD;
&#xD;
         10. Patient having health care insurance.&#xD;
&#xD;
         11. Informed and signed consent by patient.&#xD;
&#xD;
        (DICOM = Digital Imaging and Communications in Medicine)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient enrolled in a clinical trial involving an investigative new agent.&#xD;
&#xD;
          2. Co morbidity, preventing patient to tolerate the proposed standard treatment.&#xD;
&#xD;
          3. Past history of invasive cancer over the 5 years preceding entry in the present trial&#xD;
             (except basal cell carcinoma and carcinoma in situ of the cervix).&#xD;
&#xD;
          4. Impossibility to carry out evaluation by MRI (patient claustrophobic, pacemaker,&#xD;
             metallic implant, non availability, other), ), if FIGO ≥ IB2 .&#xD;
&#xD;
          5. Patient deprived from ability to decide on her own.&#xD;
&#xD;
          6. Patient unable to have a regular follow up for geographical, social or psychological&#xD;
             reasons.&#xD;
&#xD;
          7. Pregnancy or patient old enough to procreate and not using effective contraceptive&#xD;
             method.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Groupe Hospitalier Bichat</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil - CHI Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer de Montpellier - Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine - ICL</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - RENE GAUDUCHEAU</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insitut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine- ICL NANCY</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mhh Hanover - Hanover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <state>Meibergdreef</state>
        <zip>91105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherland Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1006 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teo Health S.A. - Spitalul Sf. Constantin</name>
      <address>
        <city>Brasov</city>
        <zip>500091</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal &quot;Gavril Curteanu&quot;</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de radioterapie</name>
      <address>
        <city>Timisoara</city>
        <zip>300041</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for operative oncology, Institute of oncology of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>Tumor biopsies</keyword>
  <keyword>Standard treatment</keyword>
  <keyword>Molecular profile</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

